Nanoviricides (NNVC) Return on Capital Employed Growth (1y) (2012 - 2026)
Nanoviricides (NNVC) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 45.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -785.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,629.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3,193.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 399.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -310.00 |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 2,243.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,243.00 |
| Dec 31, 2025 | -111.00 |
| Sep 30, 2025 | -2,032.00 |
| Jun 30, 2025 | -3,914.00 |
| Mar 31, 2025 | -1,841.00 |
| Dec 31, 2024 | -1,888.00 |
| Sep 30, 2024 | -2,915.00 |
| Jun 30, 2024 | -2,698.00 |
| Mar 31, 2024 | -4,740.00 |
| Dec 31, 2023 | -3,818.00 |
| Sep 30, 2023 | -2,950.00 |
| Jun 30, 2023 | -1,805.00 |
| Mar 31, 2023 | -414.00 |
| Dec 31, 2022 | -240.00 |
| Sep 30, 2022 | -49.00 |
| Jun 30, 2022 | -588.00 |
| Mar 31, 2022 | -404.00 |
| Dec 31, 2021 | -136.00 |
| Sep 30, 2021 | 33.00 |
| Jun 30, 2021 | 1,620.00 |